Literature DB >> 2581643

Effect of the cytotoxin of Clostridium difficile on cultured hepatoma cells.

B Rihn, G Beck, H Monteil, F Lecerf, R Girardot.   

Abstract

Clostridium difficile is the major etiologic agent of human pseudomembranous colitis. It produces two toxins: an enterotoxin and a cytotoxin. In cultured hepatoma cells, at very low doses, the cytotoxin inhibits the incorporation of precursors into biological macromolecules. Protein synthesis is more affected than RNA and DNA synthesis. The toxin also induces severe alterations of the cell morphology consisting in damages to the cytoskeleton and to the cell shape.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2581643     DOI: 10.1111/j.1768-322x.1985.tb00351.x

Source DB:  PubMed          Journal:  Biol Cell        ISSN: 0248-4900            Impact factor:   4.458


  5 in total

Review 1.  Clostridium difficile: its disease and toxins.

Authors:  D M Lyerly; H C Krivan; T D Wilkins
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

2.  Identification of cells responsible for synthesis of sulphated glycosaminoglycans in schistosome-induced hepatic granulomas.

Authors:  L C Silva; R Borojevic; P A Mourão
Journal:  Int J Exp Pathol       Date:  1990-12       Impact factor: 1.925

Review 3.  Clostridium difficile: clinical disease and diagnosis.

Authors:  F C Knoop; M Owens; I C Crocker
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

4.  Comparison of two commercially available enzyme immunoassays for detection of Clostridium difficile in stool specimens.

Authors:  S S Altaie; P Meyer; D Dryja
Journal:  J Clin Microbiol       Date:  1994-01       Impact factor: 5.948

5.  Utility of Clostridium difficile toxin B for inducing anti-tumor immunity.

Authors:  Tuxiong Huang; Shan Li; Guangchao Li; Yuan Tian; Haiying Wang; Lianfa Shi; Gregorio Perez-Cordon; Li Mao; Xiaoning Wang; Jufang Wang; Hanping Feng
Journal:  PLoS One       Date:  2014-10-23       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.